International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(6), С. 3358 - 3358
Опубликована: Март 15, 2024
Colorectal
cancer
(CRC),
a
prevalent
malignant
tumor
of
the
digestive
system,
ranks
as
third
and
second
in
global
incidence
mortality,
respectively,
2020,
with
1.93
million
new
cases
(≈10%
all
cancers).
There
are
940,000
deaths
(≈9.4%
cancers),
CRC
younger
patients
(under
50
years
age)
has
become
trend.
The
pathogenesis
is
primarily
attributed
to
series
genetic
epigenetic
abnormalities
within
normal
colonic
epithelial
cells,
coupled
reshaping
microenvironment
surrounding
stroma.
This
process
leads
transformation
colorectal
adenomas
into
invasive
adenocarcinomas.
Although
changes
known
be
primary
driving
force
occurrence
progression
CRC,
recent
research
indicates
that
regulation
serves
crucial
molecular
marker
cancer,
playing
significant
role
pathological
physiological
control
interactions
between
genetics
environment.
review
discusses
current
epidemiology
its
risk
factors,
preventive
treatment
strategies.
study
explores
latest
advancements
including
DNA
methylation,
histone
modifications,
non-coding
RNAs
(ncRNAs).
These
developments
hold
potential
screening
tools,
prognostic
biomarkers,
therapeutic
targets
for
CRC.
Current Oncology Reports,
Год журнала:
2024,
Номер
26(10), С. 1258 - 1270
Опубликована: Июль 30, 2024
This
review
will
explore
various
strategies
to
rendering
MSS
mCRCs
susceptible
ICI.
Moreover,
we
provide
an
overview
of
potential
biomarkers
that
may
aid
better
patient
selection,
and
discuss
ongoing
efforts
in
this
area
research.
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(3), С. 1168 - 1168
Опубликована: Янв. 29, 2025
Colorectal
cancer
(CRC)
remains
the
second
most
lethal
worldwide,
with
incidence
rates
expected
to
rise
substantially
by
2040.
Although
biomarker-driven
therapies
have
improved
treatment,
responses
standard
chemotherapeutics,
such
as
5-fluorouracil
(5-FU),
oxaliplatin,
and
irinotecan,
vary
considerably.
This
clinical
heterogeneity
emphasizes
urgent
need
for
novel
biomarkers
that
can
guide
therapeutic
decisions
overcome
chemoresistance.
microRNAs
(miRNAs)
emerged
key
post-transcriptional
regulators
critically
influence
chemotherapy
responses.
miRNAs
orchestrate
gene
regulation
modulate
diverse
pathways
linked
They
drug
transport
regulating
ABC
transporters
affect
metabolic
enzymes
like
thymidylate
synthase
(TYMS).
These
activities
shape
CRC
agents.
Furthermore,
regulate
epithelial–mesenchymal
transition
(EMT).
The
miR-200
family
(e.g.,
miR-200c
miR-141)
reverse
EMT
phenotypes,
restoring
chemosensitivity.
Additionally,
miR-19a
miR-625-3p
show
predictive
value
outcomes.
Despite
these
promising
findings,
translation
of
miRNA-based
faces
challenges,
including
methodological
inconsistencies
dynamic
nature
miRNA
expression,
influenced
tumor
microenvironment.
review
highlights
critical
role
in
elucidating
chemoresistance
mechanisms
their
promise
targets
CRC,
paving
way
a
new
era
precision
oncology.
Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Сен. 3, 2024
The
aim
of
this
study
was
to
evaluate
the
prognostic
value
peripheral
blood
inflammation
indexes
in
patients
with
metastatic
Colorectal
Cancer
(CRC)
and
establish
a
predictive
scoring
system.
A
total
324
CRC
diagnosed
through
pathological
examination
from
January
2017
July
2022
at
Third
Affiliated
Hospital
Kunming
Medical
University
were
included.
prognosis
examined,
correlation
between
IL-10
expression
tissues
serum
analyzed.
results
showed
that
poorer
when
metastasis
occurred
(P
<
0.001).
Additionally,
highly
expressed
group
=
0.018),
positively
correlated
0.037).
neutrophil-to-lymphocyte
ratio
(NLR),
lymphocyte-to-white
cell
(LWR),
aggregate
index
systemic
(AISI),
monocyte-to-lymphocyte
(MLR),
inflammatory
response
(SIRI),
nutritional
(PNI),
advanced
lung
cancer
(ALI),
interleukin-10
(IL-10)
calculated
determined
by
ROC
curve.
critical
values
2.135,
3.735,
353.745,
0.265,
1.025,
52.975,
353.635,
11.25,
respectively.
Inflammatory
an
AUC
more
than
0.6
selected,
each
colorectal
patient
any
these
risk
factors
assigned
score
one.
then
divided
into
two
groups:
0–4
for
low-risk
4–8
high-risk
group.
occurrence
distant
metastases
groups
statistically
OS
PFS
significantly
superior
those
0.05).
These
findings
indicate
NLR,
LWR,
AISI,
MLR,
SIRI,
PNI,
ALI,
are
patients.
Therefore,
prediction
scores
can
be
used
effectively
CRC.
Frontiers in Immunology,
Год журнала:
2025,
Номер
15
Опубликована: Янв. 14, 2025
Colorectal
cancer
(CRC)
remains
a
significant
cause
of
cancer-related
mortality
worldwide.
Despite
advancements
in
surgery,
chemotherapy,
and
radiotherapy,
the
effectiveness
these
conventional
treatments
is
limited,
particularly
advanced
cases.
Therefore,
transition
to
novel
treatment
urgently
needed.
Immunotherapy,
especially
immune
checkpoint
inhibitors
(ICIs),
has
shown
promise
improving
outcomes
for
CRC
patients.
Notably,
patients
with
deficient
mismatch
repair
(dMMR)
or
microsatellite
instability-high
(MSI-H)
tumors
often
benefit
from
ICIs,
while
majority
cases,
which
exhibit
proficient
(pMMR)
microsatellite-stable
(MSS)
status,
generally
show
resistance
this
approach.
It
assumed
that
MSI
phenotype
some
changes
tumor
microenvironment
(TME),
thus
triggering
antitumor
immunity
leading
response
immunotherapy.
Understanding
differences
TME
relative
status
essential
developing
more
effective
therapeutic
strategies.
This
review
provides
an
overview
components
explores
current
approaches
aimed
at
enhancing
ICI
efficacy
MSS
CRC.
Frontiers in Oncology,
Год журнала:
2025,
Номер
14
Опубликована: Янв. 22, 2025
The
prolongation
of
survival
along
with
the
preservation
quality
life,
possibly
avoiding
harmful
cumulative
toxicities,
is
primary
therapeutic
aim
for
patients
metastatic
colorectal
cancer
(mCRC)
in
third-line
setting.
Several
options
are
now
available,
although
some
differences
across
countries
drug
approval
and
optimal
sequencing
associated
each
peculiar
patient
subgroup
represent
a
clinical
challenge
oncologists.
Among
various
options,
SUNLIGHT
trial
showed
how
combination
trifluridine/tipiracil
(FTD/TPI)
bevacizumab
effective
an
easily
manageable
toxicity
profile
compared
to
FTD/TPI
alone.
Of
note,
efficacy
confirmed
independently
from
KRAS
mutational
status
also
who
had
breaks
anti-vascular
endothelial
growth
factor
(anti-VEGF)
therapy.
Herein,
we
describe
current
state
art
landscape
treatments
after
second
progression
mCRC.
Based
on
critical
review
literature
aimed
guide
clinicians
their
daily
decision-making,
point
out
that
produces
benefit
unselected
mCRC
patients.
Therefore,
plus
regimen
can
new
standard
care
treatment
refractory
have
progressed
two
lines
Cell Communication and Signaling,
Год журнала:
2024,
Номер
22(1)
Опубликована: Май 18, 2024
Abstract
Background
While
de
novo
cholesterol
biosynthesis
plays
a
crucial
role
in
chemotherapy
resistance
of
colorectal
cancer
(CRC),
the
underlying
molecular
mechanism
remains
poorly
understood.
Methods
We
conducted
cell
proliferation
assays
on
CRC
cells
with
or
without
depletion
squalene
epoxidase
(SQLE),
5-fluorouracil
(5-FU)
treatment.
Additionally,
xenograft
mouse
model
was
utilized
to
explore
impact
SQLE
chemosensitivity
5-FU.
RNA-sequencing
analysis
and
immunoblotting
were
performed
clarify
mechanism.
further
effect
ubiquitin
NF-κB
inhibitor
alpha
(IκBα)
(S)-2,3-epoxysqualene
binding
IκBα
beta-transducin
repeat
containing
E3
protein
ligase
(BTRC)
by
using
immunoprecipitation
assay.
In
addition,
cohort
272
patients
selected
for
our
clinical
analyses.
Results
Mechanistically,
promotes
degradation
subsequent
activation
enhancing
interaction
between
BTRC
IκBα.
Activated
upregulates
expression
baculoviral
IAP
3
(BIRC3),
sustains
tumor
survival
after
5-FU
treatment
vivo.
Notably,
terbinafine,
an
commonly
used
as
antifungal
drug
clinic,
enhances
sensitivity
is
associated
prognosis
human
5-FU-based
chemotherapy.
Conclusions
Thus,
finding
not
only
demonstrates
new
chemoresistance
CRC,
but
also
reveals
novel
(S)-2,3-epoxysqualene-dependent
activation,
implicating
combined
potential
terbinafine
Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Июнь 25, 2024
Abstract
Colon
cancer
ranks
as
the
third
most
prevalent
form
of
globally,
with
chemotherapy
remaining
primary
treatment
modality.
To
mitigate
drug
resistance
and
minimize
adverse
effects
associated
chemotherapy,
selection
appropriate
adjuvants
assumes
paramount
importance.
Caffeic
acid
phenethyl
ester
(CAPE),
a
naturally
occurring
compound
derived
from
propolis,
exhibits
diverse
array
biological
activities.
We
observed
that
addition
CAPE
significantly
augmented
sensitivity
colon
cells
to
oxaliplatin.
In
SW480
HCT116
cells,
oxaliplatin
combined
10
µM
reduced
IC
50
14.24
±
1.03
84.16
3.02
2.11
0.15
3.92
0.17
µM,
respectively.
then
used
proteomics
detect
differentially
expressed
proteins
in
CAPE-treated
found
main
showing
changes
expression
after
were
p62
(SQSTM1)
LC3B
(MAP1LC3B).
Gene
ontology
analysis
revealed
exerted
antitumor
chemotherapy-sensitization
through
autophagy
pathway.
subsequently
verified
using
immunoblotting.
Simultaneously,
inhibitor
bafilomycin
A1
mCherry-EGFP-LC3
reporter
gene
controls
effect
on
levels.
Collectively,
results
indicate
may
exert
chemotherapy-sensitizing
by
inhibiting
autophagy,
offering
novel
insights
for
development
potential
chemosensitizing
agents.
